AB
CORT icon

Amalgamated Bank’s Corcept Therapeutics CORT Stock Holding History

Amalgamated Bank’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Sell
30,240
-1,701
-5% -$103K 0.02% 704
2026
Q1 		$1.29M Sell
31,941
-926
-3% -$34.6K 0.01% 978
2025
Q4 		$1.14M Buy
32,867
+1,259
+4% +$98.9K 0.01% 1018
2025
Q3 		$2.63M Buy
31,608
+1,011
+3% +$73.2K 0.02% 702
2025
Q2 		$2.25M Buy
30,597
+4,429
+17% +$321K 0.02% 742
2025
Q1 		$2.99M Sell
26,168
-777
-3% -$47.3K 0.03% 598
2024
Q4 		$1.36M Sell
26,945
-84
-0.3% -$4.4K 0.01% 934
2024
Q3 		$1.25M Sell
27,029
-606
-2% -$21.5K 0.01% 970
2024
Q2 		$898K Sell
27,635
-627
-2% -$17.2K 0.01% 1075
2024
Q1 		$712K Sell
28,262
-8,876
-24% -$210K 0.01% 1182
2023
Q4 		$1.21M Sell
37,138
-1,379
-4% -$37.9K 0.01% 1091
2023
Q3 		$1.05M Sell
38,517
-1,439
-4% -$41.6K 0.01% 1093
2023
Q2 		$889K Sell
39,956
-2,438
-6% -$56.1K 0.01% 1168
2023
Q1 		$918K Sell
42,394
-2,694
-6% -$59.1K 0.01% 1151
2022
Q4 		$916K Sell
45,088
-82
-0.2% -$2.06K 0.01% 1188
2022
Q3 		$1.16M Buy
45,170
+831
+2% +$22.2K 0.01% 1057
2022
Q2 		$1.05M Sell
44,339
-1,193
-3% -$26K 0.01% 1137
2022
Q1 		$1.02M Sell
45,532
-3,903
-8% -$83K 0.01% 1188
2021
Q4 		$979K Sell
49,435
-4,470
-8% -$90.7K 0.01% 1241
2021
Q3 		$1.06M Sell
53,905
-991
-2% -$20.7K 0.01% 1217
2021
Q2 		$1.21M Buy
54,896
+40,135
+272% +$893K 0.01% 1200
2021
Q1 		$351K Sell
14,761
-1,343
-8% -$35.9K 0.01% 1187
2020
Q4 		$421K Buy
16,104
+351
+2% +$7.39K 0.02% 1056
2020
Q3 		$274K Sell
15,753
-517
-3% -$8.24K 0.01% 1154
2020
Q2 		$274K Sell
16,270
-1,756
-10% -$24.7K 0.01% 1161
2020
Q1 		$214K Sell
18,026
-790
-4% -$9.78K 0.01% 1329
2019
Q4 		$228K Buy
18,816
+584
+3% +$8.13K ﹤0.01% 1570
2019
Q3 		$258K Sell
18,232
-185
-1% -$2.27K 0.01% 1407
2019
Q2 		$205K Buy
18,417
+2,247
+14% +$25K ﹤0.01% 1580
2019
Q1 		$190K Buy
16,170
+276
+2% +$3.43K ﹤0.01% 1518
2018
Q4 		$212K Buy
+15,894
New +$210K 0.01% 1381
2018
Q3 		– Sell
-15,843
Closed -$249K – 1484
2018
Q2 		$249K Buy
15,843
+2,663
+20% +$46.3K 0.01% 1435
2018
Q1 		$217K Sell
13,180
-212
-2% -$3.93K 0.01% 1407
2017
Q4 		$242K Buy
13,392
+1,813
+16% +$32.8K 0.01% 1380
2017
Q3 		$223K Sell
11,579
-59
-0.5% -$880 0.01% 1383
2017
Q2 		$137K Buy
+11,638
New +$126K ﹤0.01% 1490

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Amalgamated Bank's CORT Position: Q2 2026 in Review

Amalgamated Bank reduced its Corcept Therapeutics (CORT) stake by 5.3% in Q2 2026, selling an estimated $103K and leaving 30,240 shares worth $2.63M. The position accounts for 0.02% of the portfolio, ranked #704.

Amalgamated Bank first reported a position in CORT in Q2 2017 and has held it in 36 quarters since. The position peaked at $2.99M in Q1 2025. 205 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Amalgamated Bank held 30,240 shares of Corcept Therapeutics worth $2.63M as of Q2 2026.
  • Amalgamated Bank sold 1,701 Corcept Therapeutics shares in Q2 2026, an estimated $103K.
  • Corcept Therapeutics made up 0.02% of Amalgamated Bank's portfolio in Q2 2026, its #704 holding.
  • Amalgamated Bank first reported a position in Corcept Therapeutics in Q2 2017 and has held it in 36 quarters since.
  • Amalgamated Bank's Corcept Therapeutics position peaked at $2.99M in Q1 2025.
  • 205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.